title: Absence of gender disparity in short-term clinical outcomes in patients with acute ST-segment elevation myocardial infarction undergoing sirolimus-eluting stent based primary coronary intervention: a report from Shanghai Acute Coronary Event (SACE) Registry.
abstract: BACKGROUND
  Randomized, controlled trials have demonstrated the superiority of sirolimus-eluting stent (SES) implantation during primary percutaneous coronary intervention (PCI), as opposed to bare-metal stents, in patients with ST-elevation myocardial infarction (STEMI). This study aimed to test the hypothesis that clinical benefits of SES treatment were independent of gender in this setting.
  
  
  METHODS
  A total of 2042 patients with STEMI undergoing SES-based primary PCI were prospectively enrolled into Shanghai Acute Coronary Event (SACE) registry (1574 men and 468 women). Baseline demographics, angiographic and PCI features, and in-hospital and 30-day major adverse cardiac events (MACE) were analyzed as a function of gender.
  
  
  RESULTS
  Compared with men, women were older and more frequently had hypertension, diabetes, and hypercholesterolemia. Use of platelet glycoprotein IIb/IIIa receptor inhibitor (GPI, 65.5% vs. 62.2%, P = 0.10) and procedural success rate (95.0% vs. 94.2%, P = 0.52) were similar in both genders. In-hospital death and MACE occurred in 3.8% and 7.6%, and 4.5% and 8.1% in the male and female patients, respectively (all P > 0.05). At 30-day follow-up, survival (94.3% vs. 93.8%, P = 0.66) and MACE-free survival (90.2% vs. 89.3%, P = 0.52) did not significantly differ between men and women. After adjustment for differences in patient demographics, angiographic and procedural features, there were no significant difference in either in-hospital (OR = 0.77, 95%CI of 0.48 to 1.22, P = 0.30) or 30-day mortality (OR = 1.28, 95%CI of 0.73 to 2.23, P = 0.38) between women and men.
  
  
  CONCLUSIONS
  Despite more advanced age and clustering of risk factors in women, female patients with STEMI treated by SES-based primary PCI had similar in-hospital and short-term clinical outcomes as their male counterparts.
authors.affiliation: Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Zhang
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Qiu
authors.forename: Rui-Yan
authors.initials: RY
authors.lastname: Zhang
authors.forename: Yi-Gang
authors.initials: YG
authors.lastname: Li
authors.forename: Ben
authors.initials: B
authors.lastname: He
authors.forename: Hui-Gen
authors.initials: HG
authors.lastname: Jin
authors.forename: Jun-Feng
authors.initials: JF
authors.lastname: Zhang
authors.forename: Xiao-Long
authors.initials: XL
authors.lastname: Wang
authors.forename: Li
authors.initials: L
authors.lastname: Jiang
authors.forename: Min-Lei
authors.initials: ML
authors.lastname: Liao
authors.forename: Jian
authors.initials: J
authors.lastname: Hu
authors.forename: Wei-Feng
authors.initials: WF
authors.lastname: Shen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002681:China; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy*; D011446:Prospective Studies; D012042:Registries; D012737:Sex Factors; D020123:Sirolimus / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D020123:Sirolimus